FibroGen, Inc (FGEN): Price and Financial Metrics

FibroGen, Inc (FGEN): $26.16

0.32 (+1.24%)

POWR Rating

Component Grades













Add FGEN to Watchlist
Sign Up

Industry: Biotech


of 484

in industry


  • Growth is the dimension where FGEN ranks best; there it ranks ahead of 88.41% of US stocks.
  • The strongest trend for FGEN is in Momentum, which has been heading down over the past 31 weeks.
  • FGEN ranks lowest in Momentum; there it ranks in the 5th percentile.

FGEN Stock Summary

  • Of note is the ratio of Fibrogen Inc's sales and general administrative expense to its total operating expenses; only 11.98% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Fibrogen Inc is higher than it is for about only 12.14% of US stocks.
  • As for revenue growth, note that FGEN's revenue has grown -25.97% over the past 12 months; that beats the revenue growth of just 14.92% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Fibrogen Inc are ACRS, CUE, XAIR, ARVN, and APTX.
  • FGEN's SEC filings can be seen here. And to visit Fibrogen Inc's official web site, go to

FGEN Price Target

For more insight on analysts targets of FGEN, see our FGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $40.57 Average Broker Recommendation 1.75 (Moderate Buy)

FGEN Stock Price Chart Interactive Chart >

Price chart for FGEN

FGEN Price/Volume Stats

Current price $26.16 52-week high $57.21
Prev. close $25.84 52-week low $18.12
Day low $25.70 Volume 224,067
Day high $26.50 Avg. volume 1,258,018
50-day MA $21.53 Dividend yield N/A
200-day MA $36.99 Market Cap 2.41B

FibroGen, Inc (FGEN) Company Bio

Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.

FGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

FGEN Latest Social Stream

Loading social stream, please wait...

View Full FGEN Social Stream

Latest FGEN News From Around the Web

Below are the latest news stories about Fibrogen Inc that investors may wish to consider to help them evaluate FGEN as an investment opportunity.

Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM adaptive trial platform evaluating pamrevlumab [and standard of care] for patients with metastatic pancreatic cancer. The objective of Precision Promise is to expedite the study and approval of promising therapies for pancreatic cancer by bringing multiple stakeholders together, including academic, indust

Yahoo | June 16, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities and/or sold put op

Yahoo | June 14, 2021

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FGEN, PCT and ARRY

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

Yahoo | June 11, 2021

DEADLINE TODAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April ...

Yahoo | June 11, 2021

CLASS ACTION UPDATE for FGEN, CS and CCXI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

Yahoo | June 11, 2021

Read More 'FGEN' Stories Here

FGEN Price Returns

1-mo 26.07%
3-mo -23.33%
6-mo -40.50%
1-year -35.61%
3-year -56.18%
5-year 67.80%
YTD -29.47%
2020 -13.52%
2019 -7.32%
2018 -2.36%
2017 121.50%
2016 -29.77%

Continue Researching FGEN

Here are a few links from around the web to help you further your research on Fibrogen Inc's stock as an investment opportunity:

Fibrogen Inc (FGEN) Stock Price | Nasdaq
Fibrogen Inc (FGEN) Stock Quote, History and News - Yahoo Finance
Fibrogen Inc (FGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.8887 seconds.